ArticleMolecular biotechnology2026
Caffeine Sodium Benzoate Promotes Endothelial Dysfunction of Human Umbilical Vein Endothelial Cells by Promoting M1 Macrophage Polarization.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous study uncovered that long-term abuse of caffeine sodium benzoate (CSB) could lead to dysfunction in human umbilical vein endothelial cells (HUVECs). However, the mechanism by which CSB induced endothelial dysfunction remains largely unstudied. CSB containing serum (CSB-CS) was collected from patients under long-term CSB inhalation. RAW264.7 cells were treated with different concentrations of CSB-CS, after which the conditioned medium (CM) was collected and cultured with HUVECs. The migration, tube formation, and senescence of HUVECs were evaluated. CSB-CS could induce polarization of RAW264.7 cells toward the M1 phenotype, as evidenced by the elevated CD86 and iNOS levels. Additionally, the CM from CSB-treated RAW264.7 cells notably suppressed the migration, tube formation, and induced cell senescence and endothelial dysfunction in HUVECs. Moreover, the CM from CSB-treated RAW264.7 cells greatly reduced mitochondrial membrane potential level, increased the ROS production, reduced OPA1 levels, but elevated DRP1 levels in HUVECs, leading to mitochondrial fission and dysfunction. Meanwhile, the CM from CSB-treated RAW264.7 cells remarkably reduced p-AKT and p-GSK3β levels in HUVECs. Notably, promotion of mitochondrial fusion by MASM7 could mitigate mitochondrial dysfunction and endothelial dysfunction in HUVECs induced by the CM from CSB-treated RAW264.7 cells. Collectively, we found that CSB could induce mitochondrial dysfunction in HUVECs by the polarization of pro-inflammatory M1 macrophages, resulting in endothelial dysfunction. These findings may provide a foundational basis for developing treatments for diseases associated with CSB.
Indexed as
Identifiers
39987548What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.